Search
ImmuCell Corp
ICCCAdd to Watchlist
10.290USD
-0.710-6.45%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
93.09MMarket Cap
LossP/E TTM
More Details of ImmuCell Corp Company
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
ImmuCell Corp Info
Ticker SymbolICCC
Company nameImmuCell Corp
IPO dateMay 01, 1987
CEOte Boekhorst (Olivier)
Number of employees69
Security typeOrdinary Share
Fiscal year-endMay 01
Address56 Evergreen Drive
CityPORTLAND
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code04103
Phone12078782770
Websitehttps://immucell.com/
Ticker SymbolICCC
IPO dateMay 01, 1987
CEOte Boekhorst (Olivier)
Company Executives of ImmuCell Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
216.70K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
131.39K
-1.55%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--
Mr. Steven T. Rosgen
Mr. Steven T. Rosgen
Independent Director
Independent Director
--
--
Ms. Gloria J. Basse
Ms. Gloria J. Basse
Independent Director
Independent Director
--
--
Mr. Timothy C. Fiori
Mr. Timothy C. Fiori
Chief Financial Officer, Treasurer, Secretary, Director
Chief Financial Officer, Treasurer, Secretary, Director
--
--
Mr. Olivier te Boekhorst
Mr. Olivier te Boekhorst
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
216.70K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
131.39K
-1.55%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--
Mr. Steven T. Rosgen
Mr. Steven T. Rosgen
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of ImmuCell Corp?
The top five shareholders of ImmuCell Corp are: Mr. Michael F. Brigham
How many institutions hold shares of ImmuCell Corp (ICCC)?
As of 2026Q1, 48 institutions hold shares of ImmuCell Corp, with a combined market value of approximately 2.16M, accounting for 23.86% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 228934.00.
What is the biggest source of revenue for ImmuCell Corp?
In 2026Q1, the First Defense® product line business generated the highest revenue for ImmuCell Corp, amounting to 27.45M and accounting for 99.29% of total revenue.